Antigen-specific suppression of experimental autoimmune encephalomyelitis by a novel bifunctional peptide inhibitor

J Pharmacol Exp Ther. 2007 Aug;322(2):879-86. doi: 10.1124/jpet.107.123257. Epub 2007 May 23.

Abstract

The objective of this study is to evaluate the activity of a novel peptide, i.e., bifunctional peptide inhibitor (BPI), which targets the immunological synapse and inhibits autoimmune responses in an antigen-specific manner. Proteolipid protein (PLP)-BPI was designed by conjugating two peptides, an encephalitogenic epitope of proteolipid protein (PLP(139-151)) and an intercellular adhesion molecule-1-binding peptide derived from alpha(L) integrin (CD11a(237-246)), via a spacer peptide. The therapeutic effect of PLP-BPI was studied in experimental autoimmune encephalomyelitis (EAE) in female SJL/J mice as a model for human multiple sclerosis. Mice that received i.v. injections of PLP-BPI showed significantly lower EAE disease scores and incidence than those treated with vehicle, PLP(139-151) peptide only, CD11a(237-246) peptide only, unlinked mixture of PLP(139-151), and CD11a(237-246) peptides, or other control peptides. Multiple injections of antigenic peptide can produce anaphylactic responses; interestingly, PLP-BPI-treated animals have significantly lower anaphylactic response than do the PLP(139-151)-treated group. Therefore, PLP-BPI can effectively inhibit the disease severity and incidence of EAE with a lower possibility of inducing fatal anaphylaxis. These results suggest that BPI-type molecules can be used to treat different autoimmune diseases in which antigenic epitopes have been identified.

Publication types

  • Research Support, N.I.H., Extramural
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Amino Acid Sequence
  • Anaphylaxis / chemically induced
  • Anaphylaxis / immunology
  • Animals
  • Antigens / chemistry
  • Antigens / immunology
  • Antigens / therapeutic use*
  • Body Weight / drug effects
  • CD11a Antigen / chemistry
  • Capsid Proteins / chemistry
  • Encephalomyelitis, Autoimmune, Experimental / drug therapy*
  • Encephalomyelitis, Autoimmune, Experimental / immunology
  • Encephalomyelitis, Autoimmune, Experimental / pathology
  • Female
  • Interferon-gamma / metabolism
  • Interleukin-10 / metabolism
  • Interleukin-4 / metabolism
  • Mice
  • Mice, Inbred Strains
  • Models, Immunological
  • Molecular Sequence Data
  • Myelin Proteolipid Protein / chemistry
  • Myelin Proteolipid Protein / immunology
  • Ovalbumin / chemistry
  • Peptide Fragments / chemistry
  • Peptide Fragments / immunology
  • Peptides / immunology
  • Peptides / therapeutic use*
  • Peptides / toxicity
  • Spleen / cytology
  • Spleen / immunology
  • T-Lymphocyte Subsets / drug effects
  • T-Lymphocyte Subsets / immunology
  • T-Lymphocyte Subsets / metabolism
  • T-Lymphocytes, Regulatory / immunology
  • T-Lymphocytes, Regulatory / metabolism
  • Time Factors
  • Transforming Growth Factor beta / metabolism
  • Vaccination

Substances

  • Antigens
  • CD11a Antigen
  • Capsid Proteins
  • Myelin Proteolipid Protein
  • PLP-BPI peptide
  • Peptide Fragments
  • Peptides
  • Transforming Growth Factor beta
  • VP2 protein, Theilovirus
  • myelin proteolipid protein (139-151)
  • Interleukin-10
  • Interleukin-4
  • Interferon-gamma
  • Ovalbumin